Physician profile
Michael Scott Weingarten
NPI 1750590253
$4,056.13
in general payments reported to CMS, 2019-2025
27 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $195 · 2021: $404 · 2022: $583 · 2023: $392 · 2024: $936 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,419 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,419.09 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,010.81 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $636.79 | 2020-2025 | |
| Amgen INC. | $476.95 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Abbvie INC. | $378.76 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $195.09 | 2022-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $139.83 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $124.19 | 2021-2025 | Benlysta |
| Radius Health, INC. | $110.90 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $109.81 | 2021-2025 | |
| Genentech USA, INC. | $109.70 | 2019-2025 | Actemra, Gazyva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.50 | 2023-2025 | Ofev, Cyltezo |
| Sandoz INC. | $90.36 | 2023-2025 | Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $82.10 | 2019-2024 | Orencia |
| Lilly USA, LLC | $71.42 | 2019-2024 | Taltz |
| Fresenius Kabi USA, LLC | $60.74 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $46.72 | 2024-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $46.55 | 2024-2025 | Strensiq |
| Octapharma USA, INC. | $44.25 | 2024-2025 | Octagam Immune Globulin (Human) |
| Actelion Pharmaceuticals US, INC. | $34.84 | 2024 | Opsumit, Uptravi |
| Genzyme Corporation | $34.02 | 2025 | |
| Kyowa Kirin, INC. | $29.82 | 2024 | Crysvita |
| Invivyd INC | $25.15 | 2025 | Pemgarda |
| Daiichi Sankyo INC. | $24.60 | 2025 | Injectafer |
| Ani Pharmaceuticals, INC. | $21.94 | 2025 | Purified Cortrophin Gel |
| Sobi, INC | $21.46 | 2025 | |
| Merck Sharp & Dohme LLC | $15.06 | 2019 | |
| Horizon Therapeutics Plc | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weingarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.